Application Detail

Description of Medical Service

Imlifidase is a treatment used to prevent the body from rejecting a newly transplanted kidney. It is used before transplantation in people who have antibodies against the donor kidney and are considered ’highly sensitised’ based on a positive crossmatch test. It is a desensitisation treatment, used to convert people from crossmatch positive, to negative and therefore reducing the likelihood of the recipient's body rejecting the donated kidney.

Description of Medical Condition

End-stage kidney disease is defined by partial or completely failed kidney function. Patients require regular dialysis or a kidney transplant for survival.

Reason for Application

Highly Specialised Therapy-National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

1732

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 238 KB)
Application Summary (Word 60 KB)

PICO Set (PDF 550 KB)
PICO Set (Word 211 KB)

Consultation Survey

Consultation Survey (PDF 653 KB)
Consultation Survey (Word 32 KB)

PASC Consultation
Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 14 June 2024 for it to be considered by MSAC at its August 2024 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Bypassing PASC

ESC

13-14 June 2024

MSAC

1-2 August 2024